Kala Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 12.84 million compared to USD 47.57 million a year ago. Basic loss per share from continuing operations was USD 7.97 compared to USD 33.94 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | +1.94% | -4.40% | -10.00% |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
Mar. 29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.00% | 17.74M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022